In Section C, participants will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Participants will obtain treatment right up until sickness progression or the contributors are not able to tolerate the study drugs. Celastrol was determined to be